Discovery, biological evaluation, and structure-activity and -selectivity relationships of 6′-substituted (E)-2-(benzofuran-3(2H)-ylidene)-N- methylacetamides, a novel class of potent and selective monoamine oxidase inhibitors

Journal of Medicinal Chemistry

Volumn 56, Issue 6, 2013, Pages 2651-2664

  Pisani, Leonardo ^a   Barletta, Maria ^a   Soto Otero, Ramon ^b   Nicolotti, Orazio ^a   Mendez Alvarez, Estefania ^b   Catto, Marco ^a   Introcaso, Antonellina ^a   Stefanachi, Angela ^a   Cellamare, Saverio ^a   Altomare, Cosimo ^a   Carotti, Angelo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 (METHYLAMINO) 2 OXOETHYLIDENE] 2,3 DIHYDRO 1 BENZOFURAN 6 YL 3,3,3 TRIFLUOROPROPANE 1 SULFONATE; 7 METHYL 3 [2 (METHYLAMINO) 2 OXOETHYLIDENE] 2,3 DIHYDRO 1 BENZOFURAN 6 YL 3,3,3 TRIFLUOROPROPANE 1 SULFONATE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; IPRONIAZID; MONOAMINE OXIDASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CHEMICAL BOND; CHEMICAL MODIFICATION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEPRESSION; DRUG SCREENING; DRUG SYNTHESIS; INHIBITION KINETICS; MALE; MOLECULAR DOCKING; NONHUMAN; PARKINSON DISEASE; RAT; STRUCTURE ACTIVITY RELATION;

BENZOFURANS; DRUG DISCOVERY; HUMANS; MOLECULAR DOCKING SIMULATION; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PROTEIN CONFORMATION; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84875721627     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4000769     Document Type: Article

References (63)

1. Youdim, M. B. H.; Finberg, J. P. M.; Tipton, K. F. In Catecholamine II. Handbook of Experimental Pharmacology; Trendelenburg, U., Weiner, N., Eds.; Springer: Berlin, 1988; pp 127-199.
2. Shih, J. C.; Chen, K.; Ridd, M. J. Monoamine Oxidase: From Genes to Behaviour Annu. Rev. Neurosci. 1999, 22, 197-217
3. Youdim, M. B.; Edmondson, D.; Tipton, K. F. The Therapeutic Potential of Monoamine Oxidase Inhibitors Nat. Rev. Neurosci. 2006, 7, 295-309
4. O'Carroll, A.-M.; Fowler, C. J.; Phillips, J. P.; Tobbia, I.; Tipton, K. F. The Deamination of Dopamine by Human Brain Monoamine Oxidase. Specificity for the Two Enzyme Forms in Seven Brain Regions Naunyn Schmiedeberg's Arch. Pharmacol. 1983, 322, 198-202
5. Grimsby, J.; Lan, N. C.; Neve, R.; Chen, K.; Shih, J. C. Tissue Distribution of Human Monoamine Oxidase-A and Oxidase-B Messenger-RNA J. Neurochem. 1990, 55, 1166-1169
6. 11C-Labeled Suicide Inactivators and PET Science 1987, 235, 481-485
7. Binda, C.; Li, M.; Hubalek, F.; Restelli, N.; Edmondson, D. E.; Mattevi, A. Insights into the Mode of Inhibition of Human Mitochondrial Monoamine Oxidase B from High-Resolution Crystal Structures Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 9750-9755
8. Binda, C.; Wang, J.; Pisani, L.; Caccia, C.; Carotti, A.; Salvati, P.; Edmondson, D. E.; Mattevi, M. Structures of Human Monoamine Oxidase B Complexes with Selective Noncovalent Inhibitors: Safinamide and Coumarin Analogs J. Med. Chem. 2007, 50, 5848-5852
9. Son, S.-Y.; Jichun, Ma, J.; Kondou, Y.; Yoshimura, M.; Yamashita, E.; Tsukihara, T. Structure of Human Monoamine Oxidase A at 2.2-Å Resolution: The Control of Opening the Entry for Substrates/inhibitors Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 5739-5744
10. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, D. E.; Mattevi, A. Three-Dimensional Structure of Human Monoamine Oxidase A (MAO A): Relation to the Structures of Rat MAO A and Human MAO B Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 12684-12689
11. Binda, C.; Newton-Vinson, P.; Hubálek, F.; Edmondson, D. E.; Mattevi, A. Structure of Human Monoamine Oxidase B, a Drug Target for the Treatment of Neurological Disorders Nat. Struct. Mol. Biol. 2002, 9, 22-26
12. Edmondson, D. E.; Mattevi, A.; Binda, C.; Li, M.; Hubálek, F. Structure and Mechanism of Monoamine Oxidase Curr. Med. Chem. 2004, 11, 1983-1993
13. Anderson, M. C.; Hasan, F.; McCrodden, J. M.; Tipton, K. F. Monoamine Oxidase Inhibitors and the Cheese Effect Neurochem. Res. 1993, 18, 1145-1149
14. Benaim, S.; Dixon, M. F. Jaundice Associated with Administration of Iproniazid Br. Med. J. 1958, 2, 1068-1070
15. Levin, H. G.; Berk, J. E.; Paul, L. J.; Berman, C. Hepatitis Associated with Iproniazid (Marsilid); Report of 3 Cases Am. J. Dig. Dis. 1959, 4, 297-305
16. Wimbiscus, M.; Kostenko, O.; Malone, D. MAO Inhibitors: Risks, Benefits, and Lore Cleveland Clin. J. Med. 2010, 77, 859-882
17. Parkinson Study Group. A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations: The PRESTO Study Arch. Neurol. 2005, 62, 241-248
18. Pisani, L.; Catto, M.; Leonetti, F.; Nicolotti, O.; Stefanachi, A.; Campagna, F.; Carotti, A. Targeting Monoamine Oxidases with Multipotent Ligands: An Emerging Strategy in the Search of New Drugs against Neurodegenerative Diseases Curr. Med. Chem. 2011, 18, 4568-4587
19. Husain, M.; Shukla, R.; Dikshit, M.; Maheshwari, P. K.; Nag, D.; Srimal, R. C.; Seth, P. K.; Khanna, V. K. Altered Platelet Monoamine Oxidase-B Activity in Idiopathic Parkinson's Disease Neurochem. Res. 2009, 34, 1427-1432
20. Saura, J.; Luque, J. M.; Cesura, A. M.; Da Prada, M.; Chan-Palay, V.; Huber, G.; Loffler, J.; Richards, J. G. Increased Monoamine Oxidase B Activity in Plaque-Associated Astrocytes of Alzheimer Brains Revealed by Quantitative Enzyme Radioautography Neuroscience 1994, 62, 15-30
21. Henchcliffe, C.; Schumacher, H. C.; Burgut, F. T. Recent Advances in Parkinson's Disease Therapy: Use of Monoamine Oxidase Inhibitors Expert Rev. Neurother. 2005, 5, 811-821
22. Lin, M. T.; Beal, M. F. Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases Nature 2006, 443, 787-795
23. Ray, P. D.; Huang, B. W.; Tsuji, Y. Reactive Oxygen Species (ROS) Homeostasis and Redox Regulation in Cellular Signaling Cell. Signalling 2012, 981-990
24. Lin, M. T.; Beal, M. F. Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases Nature 2006, 443, 787-795
25. Olanow, C. W. Oxidation Reactions in Parkinson's Disease Neurology 1990, 40, 32-37
26. Zecca, L.; Youdim, M. B. H.; Riederer, P.; Connor, J. R.; Crichton, R. R. Iron, Brain Ageing and Neurodegenerative Disorders Nat. Rev. Neurosci. 2004, 5, 863-873
27. Naoi, M.; Maruyama, W. Monoamine Oxidase Inhibitors as Neuroprotective Agents in Age-Dependent Neurodegenerative Disorders Curr. Pharm. Des. 2010, 16, 2799-2817
28. Magyar, K.; Szende, B. (-)-Deprenyl, a Selective MAO-B Inhibitor, with Apoptotic and Anti-Apoptotic Properties Neurotoxicology 2004, 25, 233-242
29. Youdim, M. B. H.; Buccafusco, J. J. Multi-Functional Drugs for Various CNS Targets in the Treatment of Neurodegenerative Disorders Trends Pharmacol. Sci. 2005, 26, 27-35
30. Sterling, J.; Herzig, Y.; Goren, T.; Finkelstein, N.; Lerner, D.; Goldenberg, W.; Miskolczi, I.; Molnar, S.; Rantal, F.; Tamas, T.; Toth, G.; Zagyva, A.; Zekany, A.; Lavian, G.; Gross, A.; Friedman, R.; Razin, M.; Huang, W.; Krais, B.; Chorev, M.; Youdim, M. B. H.; Weinstock, M. Novel Dual Inhibitors of AChE and MAO Derived from Hydroxy Aminoindan and Phenethylamine as Potential Treatment for Alzheimer's Disease J. Med. Chem. 2002, 45, 5260-5279
31. Carotti, A. MAOs Long March: From Toxic First-Generation Drugs to Isoform-Selective, Reversible and Multi-Target Inhibitors. Presented at the Meeting of ACS-EFMC, Frontiers in CNS and Oncology Medicinal Chemistry, Siena, Italy, October 7-9, 2007.
32. Yamada, M.; Yasuhara, H. Clinical Pharmacology of MAO Inhibitors: Safety and Future Neurotoxicology 2004, 25, 215-221
33. Fiedorowicz, J. G.; Swartz, K. L. The Role of Monoamine Oxidase Inhibitors in Current Psychiatric Practice J. Psychiatr. Pract. 2004, 10, 239-248
34. Okaecwe, T.; Swanepoel, A. J.; Petzer, A.; Bergh, J. J.; Petzer, J. P. Inhibition of Monoamine Oxidase by 8-Phenoxymethylcaffeine Derivatives Bioorg. Med. Chem. 2012, 20, 4336-4347
35. Reniers, J.; Robert, S.; Frederick, R.; Masereel, B.; Vincent, S.; Wouter, J. Synthesis and Evaluation of β-Carboline Derivatives as Potential Monoamine Oxidase Inhibitors Bioorg. Med. Chem. 2011, 19, 134-144
36. Manley-King, C. I.; Bergh, J. J.; Petzer, J. P. Inhibition of Monoamine Oxidase by Selected C5- and C6-Substituted Isatin Analogues Bioorg. Med. Chem. 2011, 19, 261-274
37. Chimenti, F.; Bolasco, A.; Manna, F.; Secci, D.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Cirilli, R.; La Torre, F.; Alcaro, S.; Ortuso, F.; Langer, T. Synthesis, Biological Evaluation and 3D-QSAR of 1,3,5-Trisubstituted- 4,5-dihydro-(1 H)-pyrazole Derivatives as Potent and Highly Selective Monoamine Oxidase A Inhibitors Curr. Med. Chem. 2006, 13, 1411-1428
38. La Regina, G.; Silvestri, R.; Gatti, V.; Lavecchia, A.; Novellino, E.; Befani, O.; Turini, P.; Agostinelli, E. Synthesis, Structure-Activity Relationships and Molecular Modeling Studies of New Indole Inhibitors of Monoamine Oxidases A and B Bioorg. Med. Chem. 2008, 16, 9729-9740
39. Maccioni, E.; Alcaro, S.; Cirilli, R.; Vigo, S.; Cardia, M. C.; Sanna, M. L.; Meleddu, R.; Yanez, M.; Costa, G.; Casu, L.; Matyus, P.; Distinto, S. 3-Acetyl-2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoles: A New Scaffold for the Selective Inhibition of Monoamine Oxidase B J. Med. Chem. 2011, 54, 6394-6398
40. Chimenti, F.; Bolasco, A.; Secci, D.; Chimenti, P.; Granese, A.; Carradori, S.; Yáñez, M.; Orallo, F.; Ortuso, F.; Alcaro, S. Investigations on the 2-Thiazolylhydrazyne Scaffold: Synthesis and Molecular Modeling of Selective Human Monoamine Oxidase Inhibitors Bioorg. Med. Chem. 2010, 18, 5715-5723
41. Helguera, A. M.; Perez-Machado, G.; Cordeiro, M. N.; Borges, F. Discovery of MAO-B Inhibitors-Present Status and Future Directions. Part I: Oxygen Heterocycles and Analogs Mini-Rev. Med. Chem. 2012, 12, 907-919
42. Legoabe, L. J.; Petzer, A.; Petzer, J. P. Inhibition of Monoamine Oxidase by Selected C6-Substituted Chromone Derivatives Eur. J. Med. Chem. 2012, 49, 343-353
43. Matos, M. J.; Viña, D.; Picciau, C.; Orallo, F.; Santana, L.; Uriarte, E. Synthesis and Evaluation of 6-Methyl-3-phenylcoumarins as Potent and Selective MAO-B Inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 5053-5055
44. Prins, L. H. A.; Petzer, J. P.; Malan, S. F. Inhibition of Monoamine Oxidase by Indole and Benzofuran Derivatives Eur. J. Med. Chem. 2010, 45, 4458-4466
45. Matos, M. J.; Terán, C.; Pérez-Castillo, Y.; Uriarte, E.; Santana, L.; Viña, D. Synthesis and Study of a Series of 3-Arylcoumarins as Potent and Selective Monoamine Oxidase B Inhibitors J. Med. Chem. 2011, 54, 7127-7137
46. Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Bizzarri, B.; Granese, A.; Carradori, S.; Yáñez, M.; Orallo, F.; Ortuso, F.; Alcaro, S. Synthesis, Molecular Modeling, and Selective Inhibitory Activity against Human Monoamine Oxidases of 3-Carboxamido-7-Substituted Coumarins J. Med. Chem. 2009, 52, 1935-1942
47. Carotti, A.; Catto, M.; Leonetti, F.; Campagna, F.; Soto-Otero, R.; Mendez-Alvarez, E.; Thull, U.; Testa, B.; Altomare, C. Synthesis and Monoamine Oxidase Inhibitory Activity of New Pyridazine-, Pyrimidine- and 1,2,4-Triazine-Containing Tricyclic Derivatives J. Med. Chem. 2007, 22, 5364-5371
48. Kneubühler, S.; Thull, U.; Altomare, C.; Carta, V.; Gaillard, P.; Carrupt, P. A.; Carotti, A.; Testa, B. Inhibition of Monoamine Oxidase-B by 5 H -Indeno[1,2- c ]pyridazines: Biological Activities, Quantitative Structure-Activity Relationships (QSARs) and 3D-QSARs J. Med. Chem. 1995, 38, 3874-3883
49. Gnerre, C.; Catto, M.; Leonetti, F.; Weber, P.; Carrupt, P.-A.; Altomare, C.; Carotti, A.; Testa, B. Inhibition of Monoamine Oxidases by Functionalized Coumarin Derivatives: Biological Activities, QSARs, and 3D-QSARs J. Med. Chem. 2000, 43, 4747-4758
50. Leonetti, F.; Capaldi, C.; Pisani, L.; Nicolotti, O.; Muncipinto, G.; Stefanachi, A.; Cellamare, S.; Caccia, C.; Carotti, A. Solid-Phase Synthesis and Insights into Structure-Activity Relationships of Safinamide Analogues as Potent and Selective Inhibitors of Type B Monoamine Oxidase J. Med. Chem. 2007, 50, 4909-4916
51. Catto, M.; Nicolotti, O.; Leonetti, F.; Carotti, A.; Favia, A. D.; Soto-Otero, R.; Mendez-Alvarez, E.; Carotti, A. Structural Insights into Monoamine Oxidase Inhibitory Potency and Selectivity of 7-Substituted Coumarins from Ligand- and Target-Based Approaches J. Med. Chem. 2006, 49, 4912-4925
52. Pisani, L.; Muncipinto, G.; Miscioscia, T. F.; Nicolotti, O.; Leonetti, F.; Catto, M.; Caccia, C.; Salvati, P.; Soto-Otero, R.; Mendez-Alvarez, E.; Passeleu, C.; Carotti, A. Discovery of a Novel Class of Potent Coumarin Monoamine Oxidase B Inhibitors: Development and Biopharmacological Profiling of 7-[(3-Chlorobenzyl)oxy]-4-[(methylamino)methyl]-2 H -chromen-2-one Methanesulfonate (NW-1772) as a Highly Potent, Selective, Reversible, and Orally Active Monoamine Oxidase B Inhibitor J. Med. Chem. 2009, 52, 6685-6706
53. Carotti, A.; Melloni, P.; Thaler, F.; Caccia, C.; Maestroni, S.; Salvati, P. Substituted Aminoalkyl and Amidoalkyl Benzopyran Derivatives. WO 2006/102958 A1, 2006.
54. v. Pechmann, H. Novel Synthesis of Coumarins Ber. Dtsch. Chem. Ges. 1884, 17, 929-936
55. Fall, Y.; Santana, L.; Teijeira, M.; Uriarte, E. A Convenient Synthesis of Benzofuran-3-acetic Acids Heterocycles 1995, 41, 647-650
56. Blažzević, N.; Kolnah, D.; Belin, B.; Šunjić, V.; Kafjež, F. Hexamethylenetetramine. A Versatile Reagent in Organic Synthesis Synthesis 1979, 161-176
57. Mendez-Alvarez, E.; Soto-Otero, R.; Sanchez-Sellero, I.; Lopez-Rivadulla, L. M.; Lamas, M. Inhibition of Brain Monoamine Oxidase by Adducts of 1,2,3,4-Tetrahydroisoquinoline with Components of Cigarette Smoke Life Sci. 1997, 60, 1719-1727
58. Liebeschuetz, J. W. Evaluating Docking Programs: Keeping the Playing Field Level J. Comput.-Aided Mol. Des. 2008, 22, 229-238
59. Traut, M.; Weifenbach, H.; Teschendorf, H. J.; Hofmann, H. P. Biochemical and Pharmacological Characterization of Esuprone, a New Selective and Reversible Inhibitor of Monoamine Oxidase A Naunyn-Schmiedeberg's Arch. Pharmacol. 1992, 345 (S) R124
60. Soto-Otero, R.; Mendez-Alvarez, E.; Hermida-Ameijeiras, A.; Sanchez-Sellero, I.; Cruz-Landeira, A.; Lamas, M. L. R. Inhibition of Brain Monoamine Oxidase Activity by the Generation of Hydroxyl Radicals. Potential Implications in Relation to Oxidative Stress Life Sci. 2001, 69, 879-889
61. Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved Protein-Ligand Docking Using GOLD Proteins 2003, 52, 609-623
62. Korb, O.; Stützle, T.; Exner, T. E. Empirical Scoring Functions for Advanced Protein-Ligand Docking with PLANTS J. Chem. Inf. Model. 2009, 49, 84-96
63. Verdonk, M. L.; Chessari, G.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Willem, J.; Nissink, M.; Taylor, R. D.; Taylor, R. Modeling Water Molecules in Protein-Ligand Docking Using GOLD J. Med. Chem. 2005, 48, 6504-6515